The unrelenting fall of the pharmacological treatment of obesity

Di Dalmazi, Guido; Vicennati, Valentina; Pasquali, Renato; Pagotto, Uberto
December 2013
Endocrine (1355008X);Dec2013, Vol. 44 Issue 3, p598
Academic Journal
Nowadays pharmacological therapy to limit obesity has reached a critical stage: not only have Authorities limited the use of antiobesity drugs due to their proven inefficacy and dangerous side effects, but bariatric surgery has delivered better results. At present, when the number of obese subjects is growing exponentially worldwide and more and more pathological mechanisms inducing fat accumulation have been discovered, no drugs are available to help patients and physicians to limit one the most dreadful causes of death. Following the failures of promising drugs as sibutramine and rimonabant, many companies stopped to invest in the field of obesity pharmacotherapy. At the same time, leading Authorities have started to require more solid evidence before providing authorization for these drugs to enter the market. This review aims at revising the failed promises of antiobesity drugs and describing the few potential future candidates in order to shed some light in the still uncertain field of antiobesity drugs. It also provides a critical contribution to the ongoing debate among scientists, clinicians, patients and Authorities on the possibility to treat obesity with pharmacological drugs.


Related Articles

  • Two Weight Loss Drugs-Meridia and Xenical The Pros and Cons of Each.  // HealthFacts;Feb2004, Vol. 29 Issue 2, p3 

    Compares weight loss drugs Meridia and Xenical. Details on how the two drugs work; Side effects experienced by users; Costs of the drugs.

  • Health Canada issues warning against the use of Slim.  // Reactions Weekly;1/13/2007, Issue 1134, p3 

    This article reports that Health Canada warned consumers against the use of Slim, a weight-loss product manufactured in China. The warning comes after the health department of Hong Kong, China issued similar advice amongst concerns that the product is adulterated with sibutramine, a prescription...

  • The uphill battle facing antiobesity drugs. Daubresse, M; Alexander, G C // International Journal of Obesity;Mar2015, Vol. 39 Issue 3, p377 

    The authors reflect on the limited adoption of antibobesity drugs in clinical practice in the U.S. despite their association with short-term weight loss. They cite several antiobesity drugs that were withdrawn from the market due to the occurrence of adverse effects including sibutramine and...

  • Does Finasteride Cause Permanent Sexual Side Effects?  // Neurology Alert;Sep2012, Vol. 31 Issue 1, Special section p1 

    This section offers news briefs pertaining to pharmacology as of September 2012. A study found that finasteride, a drug used to treat male pattern baldness and symptomatic benign prostatic hypertrophy, may cause long-term sexual dysfunction. A federal appeals court in Philadelphia, Pennsylvania...

  • New Trends in Medicinal Chemistry Approaches to Antiobesity Therapy. Jinhwa Lee; Kwang-Seop Song; Jahyo Kang; Suk Ho Lee; Junwon Lee // Current Topics in Medicinal Chemistry;Apr2009, Vol. 9 Issue 6, p564 

    The prevalences of overweightedness and obesity are increasing globally at frightening rates, driven by social and economic changes. Furthermore, obesity is associated with the pathogeneses of major diseases, particularly diabetes and cardiovascular diseases. However, no satisfactorily safe,...

  • The Current Status and Future Perspectives of Studies of Cannabinoid Receptor 1 Antagonists as Anti-Obesity Agents. Hyeon-Kyu Lee; Eun Bok Choi; Chwang Siek Pak // Current Topics in Medicinal Chemistry;Apr2009, Vol. 9 Issue 6, p482 

    Since the discovery of rimonabant (Acomplia: 1), a large effort has been directed at the discovery of new, potent and selective CB1R antagonists that serve as anti obesity drugs. As a result, a number of compounds reached various stages of clinical trials by late 2008. However, the announcement...

  • ORLISTAT.  // Complete Guide to Prescription & Nonprescription Drugs 2012;2012, p622 

    The article presents information on orlistat, an antiobesity drug and lipase inhibitor, including its dosage, usage, adverse reactions, side effects, precautions when administering, and possible interaction with other drugs.

  • Management: Part II--Drugs. Lean, Mike; Finer, Nick // BMJ: British Medical Journal (International Edition);10/14/2006, Vol. 331 Issue 7572, p794 

    The article offers a look at drug treatment for obesity. Although diet and exercise play the most important role in weight loss, effective drugs against obesity should reduce energy assimilation from food or stimulate energy expenditure. The article discusses weight loss, weight maintenance,...

  • orlistat. Peters, Michael // BMA A-Z Family Medical Encyclopedia;2004, p569 

    An encyclopedia entry for "orlistat" is presented. It refers to an anti-obesity drug used with a slimming diet for the treatment of severe obesity. It is different from appetite suppressants in that orlistat acts on the gastrointestinal tract, preventing the digestion of fats by lipases. The...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics